Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26308 http://scihub22266oqcxt.onion/10.1002/jmv.26308 32672860!7404673!32672860     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (2): 831-842 Nephropedia Template TP {{tp|p=32672860|t=2021. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study |pdf=|usr=}}{{32672860}} gab.com Text Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32672860 #FOAvip Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of >/=2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-beta (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO(2) ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia. Twit Text FOAVip Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32672860 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32672860 #FOAvip English Wikipedia <ref>{{Cite pmid|32672860}}</ref> Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study #MMPMID32672860 Fernandez-Ruiz M; Lopez-Medrano F; Perez-Jacoiste Asin MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalan M; de la Calle C; Garcia-Garcia R; Gomez C; Laguna-Goya R; Lizasoain M; Martinez-Lopez J; Origuen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM J Med Virol 2021[Feb]; 93 (2): 831-842 PMID32672860show ga Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of >/=2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-beta (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO(2) ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia. |*COVID-19 Drug Treatment[MESH] |Administration, Intravenous[MESH] |Adult[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Body Temperature/drug effects[MESH] |C-Reactive Protein/metabolism[MESH] |COVID-19/immunology/mortality/virology[MESH] |Cytokine Release Syndrome/immunology/mortality/*prevention & control/virology[MESH] |Female[MESH] |Heart Rate/drug effects[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Interferon-beta/adverse effects[MESH] |L-Lactate Dehydrogenase/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Receptors, Interleukin-6/antagonists & inhibitors/genetics/immunology[MESH] |Respiratory Rate/drug effects[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/immunology/*pathogenicity[MESH] |Severity of Illness Index[MESH]Tocilizumab for the treatment of adult patients with severe COVID-19 p(epmc).pdf DeepDyve Pubget Overpricing